 |
| Editors' Choice: Story of the Week | |
 |
Commentary
2009 Sept 30, Bonnie Cunningham, MD, Associate Editor
Noteworthy for its publication in NEJM, this ECOG study chose survival as an endpoint in doubling the dose of daunorubicin to 90 mg/m2 x 3 with cytarabine at 100 mg/m2 x 7 for induction in AML adults under 60, using GM-CSF, and proposed transplant consolidation. Better CR rate (71% vs 57%) and overall survival (23.7 vs 15.7 months) were attained with the higher dose with comparable early cardiac toxicity. Interpretation of these data is difficult because only half of patients received planned consolidation and no data are given on relapse-free survival, the role of allogeneic or autologous transplant, or the effect of GM-CSF.
|
Induction With High-Dose vs Standard-Dose Daunorubicin in AML
N Engl J Med, 2009 Sept 24, HF Fernandez, et al
EXPERT COMMENTARY
Phase III study showed induction with high-dose daunorubicin significantly improved complete remission and survival rates.
|
| News | More » |
|
Groups Back CMS Proposal to Ease Restrictions on PET for Cervical Cancer
The Gray Sheet, 2009 Sept 28, M Hogan
Oncologists, imaging groups, and private payers strongly support the CMS proposal to lift coverage-with-evidence-development requirements.
|
Pralatrexate Is Approved for Peripheral T-Cell Lymphoma
Elsevier Global Medical News, 2009 Sept 25, E Mechcatie
Pralatrexate has been approved for use as a single agent for treating patients with refractory or relapsed peripheral T-cell lymphoma.
|
Panel Seeks Clarity Regarding Ductal Carcinoma in Situ
Elsevier Global Medical News, 2009 Sept 24, K Wachter
The most urgent research need is identification of patient subsets that may require less therapeutic intervention without sacrificing outcomes.
|
Hormone Therapy for Prostate Cancer Raises Heart Disease Risk
Elsevier Global Medical News, 2009 Sept 23, P Wendling
Observational study shows men treated with endocrine therapy are at increased risk of developing and dying from several types of CV disease.
|
| Journal Scans | More » |
|
Combined Liver Surgery and RFA for Liver Metastases From Endocrine Tumors
Eur J Surg Oncol, 2009 Oct 1, D Elias, et al
Use of a 1-step approach in patients with 23 liver metastases (median) permitted upgraded therapy and yielded an improved prognosis.
|
Perineural Invasion Confers Worse Outcome in Colorectal Cancer
J Clin Oncol, 2009 Sept 8, C Liebig, et al
In this retrospective study, PNI-positive status was a predictor of reduced survival in patients with colorectal cancer.
|
Biochemical Recurrence After Prostatectomy for Small-Volume or 'Insignificant' Tumors 
Urol Oncol, 2009 Sept 1, IM van Oort, et al
The 5-year risk of biochemical recurrence was 10% for patients with small-volume or 'insignificant' tumors treated surgically.
|
| What Patients Are Reading | More » |
|
Nanoparticle 'Nanobees' Deliver Bee Venom Agent to Tumors
As Reported by The Wall Street Journal, 2009 Sept 28
Nanoparticles containing melittin, a host-defense peptide in bee venom, and a special ligand permit the melittin to detach at the tumor site.
|
Microchip in a Handheld Device Senses Cancer Biomarkers
As Reported by Bloomberg.com, 2009 Sept 27
In a device similar to a Blackberry, a microchip analyzes cancer biomarkers in about 30 minutes.
|
Aspirin Reduces Colon Cancer Risk in Lynch Syndrome Patients
As Reported by The Associated Press, 2009 Sept 21
Lynch syndrome patients who took 600 mg of aspirin daily for 4 years lowered their risk of colon cancer.
|
Malignant Melanoma Tumors Shrink With New Drug Treatment
As reported by BBC News, 2009 Sept 23
Among 31 patients treated with PLX4032, 70% saw their tumors start to shrink within 2 weeks of starting therapy with the BRAF inhibitor.
|
|
| | |
| EDITORIAL BOARD
Our physician editors collaborate weekly to choose the website's top story.
VISIT SITE
| |
|
|
| | |
| NEW CME
Earn valuable credits by participating in these case-based online programs in renal cell carcinoma and leukemia.
VISIT SITE
| |
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
| | |
| CANCER POLICY FORUM
Get behind-the-headline perspectives on the politics of cancer.
VISIT SITE
| |
|
|
| | |
| When the Smoke Clears
Experts discuss the true clinical implications of watershed developments in oncology research.
VISIT SITE
| |
|
|
|
The Latest Oncology Intelligence
